Profile data is unavailable for this security.
About the company
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
- Revenue in USD (TTM)2.76bn
- Net income in USD-1.03bn
- Incorporated2023
- Employees14.50k
- LocationFortrea Holdings Inc8 Moore DriveDURHAM 27709United StatesUSA
- Fax+1 (302) 636-5454
- Websitehttps://www.fortrea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.13bn | 160.00 | -- | 13.43 | -- | 101.17 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.14bn | 61.00 | -- | 12.93 | -- | 18.20 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.15bn | 130.00 | -- | 4.62 | -- | 76.87 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.17bn | 35.00 | -- | 5.59 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Septerna Inc | 22.05m | -58.81m | 1.20bn | 75.00 | -- | 3.07 | -- | 54.23 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.21bn | 156.00 | -- | -- | -- | 865.35 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.23bn | 73.00 | -- | 5.60 | -- | 194.48 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Fortrea Holdings Inc | 2.76bn | -1.03bn | 1.26bn | 14.50k | -- | 2.17 | -- | 0.4577 | -11.38 | -11.24 | 30.33 | 6.30 | 0.8617 | -- | 4.08 | 178,058.10 | -32.08 | -- | -43.77 | -- | 18.61 | -- | -37.23 | -- | -- | -0.5534 | 0.6598 | -- | -5.14 | -- | -756.47 | -- | -- | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.35bn | 69.00 | -- | 2.63 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.38bn | 403.00 | -- | 1.84 | -- | 23.98 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.38bn | 3.00k | 47.97 | 0.8048 | 16.17 | 2.32 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.39bn | 136.00 | -- | -- | -- | 8.21 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.40bn | 54.00 | -- | 5.79 | -- | 462.55 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
Data as of Feb 11 2026. Currency figures normalised to Fortrea Holdings Inc's reporting currency: US Dollar USD
57.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 12.67m | 13.95% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2025 | 7.89m | 8.69% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.62m | 8.39% |
| Corvex Management LPas of 30 Sep 2025 | 4.51m | 4.97% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 4.07m | 4.48% |
| Sessa Capital IM LPas of 30 Sep 2025 | 3.99m | 4.40% |
| AQR Capital Management LLCas of 30 Sep 2025 | 3.74m | 4.11% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 2.96m | 3.26% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2025 | 2.65m | 2.92% |
| DWS Investments (UK) Ltd.as of 30 Sep 2025 | 2.55m | 2.81% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
